Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499020 | 0.76 | POLB (0.55) | CYP2C19ALDH1A1HPGDPOLBMAPT | |
| SCHEMBL27138796 | 0.73 | RIPK1 (0.47) | CYP2C19HIF1AALDH1A1KMT2AMEN1 | |
| SCHEMBL12360014 | 0.73 | POLB (0.47) | ALDH1A1HPGDPOLBHSD11B1KMT2A | |
| SCHEMBL5813853 | 0.72 | HMGCR (0.46) | CYP2C19HIF1AALDH1A1CYP2D6 | |
| SCHEMBL4039494 | 0.71 | ALDH1A1 (0.58) | HIF1AALDH1A1HPGDMAPTHSD11B1 | |
| SCHEMBL30062 | 0.71 | ALDH1A1 (0.58) | HIF1AALDH1A1HPGDMAPTHSD11B1 | |
| SCHEMBL8067400 | 0.71 | POLB (0.42) | CYP2C19HIF1AALDH1A1HPGDPOLB | |
| SCHEMBL22147214 | 0.71 | ALDH1A1 (0.45) | CYP2C19ALDH1A1HPGDPOLBMAPT | |
| SCHEMBL8459977 | 0.71 | ALDH1A1 (0.41) | CYP2C19ALDH1A1HPGDPOLBMAPT | |
| SCHEMBL6279720 | 0.71 | NR1H3 (0.50) | ALDH1A1HPGDPOLBHSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116735753-A | Detection method of benzoyl-L-aspartic acid dimethyl ester enantiomer | 上海司太立制药有限公司 | 2023-09-12 | — | — | CN | claimed |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | THE UNIVERSITY OF TOLEDO (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2020-08-27 | — | — | US | disclosed |
| WO-2017172476-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2017-10-05 | — | — | WO | disclosed |
| US-7514573-B2 | Processes for the manufacture of chiral and racemic forms of 3-aminotetrahydrofurans, their salts and derivatives | SAMI LABS LTD (IN) | 2009-04-07 | — | — | US | disclosed |
| US-20080255377-A1 | reduction of diesters of aspartic acid, then cyclization with the aid of sulfonic acids, hydrolysis using a base to give 3-(S)-aminotetrahydrofuran as its hydrochloride or p-toluenesulfonate salt, or as base itself | MAJEED MUHAMMED | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255377-A1 | reduction of diesters of aspartic acid, then cyclization with the aid of sulfonic acids, hydrolysis using a base to give 3-(S)-aminotetrahydrofuran as its hydrochloride or p-toluenesulfonate salt, or as base itself | AASDHPPT, DNPEP, ASNS | CYP2C19 3719/4885HIF1A 4818/4885ALDH1A1 1461/4885 |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | GOT1, ACAT1, GOT2 | CYP2C19 4450/4885HIF1A 3528/4885ALDH1A1 1848/4885 |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | GOT1, ACAT1, GOT2 | CYP2C19 4450/4885HIF1A 3528/4885ALDH1A1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.